Financial Data and Key Metrics Changes - In 2025, the company achieved total revenue growth of approximately 43% year-over-year, reaching RMB 1,150 million, with a non-GAAP operating profit of RMB 14 million, marking the first operating profitability in six years [2][11][12] - The company recorded a GAAP operating loss of RMB 179 million for the year, an improvement from a loss of RMB 437 million in 2024 [11] - Cash and cash equivalents at year-end stood at $215 million [12] Business Line Data and Key Metrics Changes - The internet business generated revenue of RMB 615 million, a 19% increase year-over-year, contributing 65% of segment revenue [12][14] - Revenue from the AI and other segments increased by 85% year-over-year to RMB 535 million, accounting for 46.5% of total revenue [14][15] - Robotics revenue grew approximately 31% for the full year, with Q4 robotics revenue reaching about RMB 60 million, up 94% year-over-year [3][12] Market Data and Key Metrics Changes - The internet business maintained a stable cash flow, generating approximately RMB 460,000 in adjusted operating profit per working day [12][14] - The robotics segment, particularly voice robots, showed significant growth, achieving 100% year-over-year growth for three consecutive quarters [3][12] Company Strategy and Development Direction - The company is focusing on integrating AI capabilities into practical tools rather than competing in model development, emphasizing user experience and operational efficiency [6][9] - The introduction of EasyClaw, an AI coworker platform, aims to enhance user engagement and drive higher conversion rates [8][9] - The company plans to maintain disciplined growth and improve transparency and disclosure as it enters a new phase of development [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued structural improvements and growth momentum in the robotics business, expecting it to become a more significant part of the revenue mix [10][11] - The company aims to leverage its cash flow from the internet business to support investments in new initiatives while maintaining profitability [11][76] - Management highlighted the importance of user experience and the need for practical applications of AI in driving future growth [6][10] Other Important Information - The company is introducing a smart wheelchair targeting developed regions, which is expected to begin shipments in Q2 2026 [4][5] - The robotics business is expected to maintain steady contributions, with a focus on voice robots and new product launches [59][60] Q&A Session Summary Question: What core workflows has the company accumulated in promoting AI products? - Management indicated that they have developed unique features in their AI products and emphasized the importance of user experience in differentiating from larger competitors [19][22] Question: What is the management's view on the sustainable economic value in the AI industry? - Management believes that different layers of the AI industry will coexist, with opportunities for application companies to thrive by being closer to user needs [26][30] Question: Can the company share metrics related to EasyCloud's user scale and usage? - Management highlighted that usage volume is a core measurement indicator for AI products, noting increased token usage since the Spring Festival [37][39] Question: What is the commercialization progress of EasyCloud? - Management stated that EasyCloud's revenue model is based on user calls, and they are focusing on providing better product capabilities to encourage user payment [45][48] Question: How does the company view its overseas expansion and product synergy? - Management emphasized the importance of establishing a strong product before building an ecosystem, with EasyClaw being a key focus for creating synergies [51][54] Question: Will the company continue to achieve profitability in 2026? - Management expressed confidence in maintaining profitability while balancing investments in new business areas, emphasizing disciplined growth [71][76]

Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][21] - The adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [11] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [12] - TIDES revenue nearly doubled, growing 96% year-over-year to RMB 11.37 billion [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [8] - Europe and China experienced declines mainly due to fluctuations in project delivery timing [8] Company Strategy and Development Direction - The company remains focused on enhancing its integrated CRDMO core business and improving operational efficiency to meet customer demand [23] - WuXi AppTec aims to sustain rapid business growth, expecting total revenue to reach RMB 51.3 billion - RMB 53 billion in 2026, with continuing operations revenue growing 18%-22% year-over-year [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic challenges, including currency exchange impacts and geopolitical uncertainties [30][31] - The company is committed to maintaining a stable and resilient adjusted non-IFRS net profit margin in 2026 [24] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [9] - The board proposed a cash dividend distribution plan totaling a record RMB 5.7 billion in 2026, maintaining a 30% annual cash dividend payout ratio [25] Q&A Session All Questions and Answers Question: How does management think about the impact of currency exchange? - Management acknowledged the FX movement and expressed confidence in their execution capabilities despite macroeconomic volatility [30] Question: How would you think about the impact of geopolitics and oil prices on your margins going forward? - Management noted that while there are potential risks to raw material costs, they have not seen direct impacts on operations and will monitor the situation closely [31] Question: What would be the next key modalities that could potentially be the new focus? - Management indicated that while peptide demand is high, they are also seeing growth in oligonucleotides, which could become a significant focus [32] Question: Have you sensed any change in client outsourcing strategy in the past six to 12 months? - Management stated that they are committed to improving capabilities and investing in capacities to meet customer needs, regardless of internal manufacturing trends in the pharmaceutical industry [35] Question: What is WuXi AppTec's positioning in oral small molecule GLP-1 CDMO business? - Management reported double-digit growth in the small molecule sector, with contributions from GLP-1 small molecules [46] Question: How do you see sustainability of TIDES business growth? - Management expressed confidence in sustained growth due to high demand for their largest products and a robust pipeline [54] Question: Can you give us some color on the general timeline that it takes for a new facility to be built? - Management stated that in China, a new facility can become fully operational in less than 12 months [57] Question: How is the current Middle East situation impacting the company's investment view in Saudi Arabia? - Management confirmed that their long-term strategy remains unchanged and they continue to engage with stakeholders in Saudi Arabia [60] Question: What is the company's view on relations between the U.S. and China? - Management expressed confidence that WuXi AppTec will not be included in the 1260H list and emphasized their transparent corporate governance [70]

Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][20] - Adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [11] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [12] - TIDES revenue almost doubled to RMB 11.37 billion in 2025, with a backlog growth of 20.2% year-over-year [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [8] - Europe and China experienced declines mainly due to fluctuations in project delivery timing [8] Company Strategy and Development Direction - The company remains focused on enhancing core capabilities and capacity to meet customer demand, with a strong emphasis on the CRDMO business model [7][23] - WuXi AppTec aims to drive operational efficiency and resilience to navigate dynamic market conditions, with a revenue guidance of RMB 51.3 billion to RMB 53 billion for 2026 [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining rapid business growth despite macroeconomic uncertainties, with a continuing operations revenue growth expectation of 18%-22% for 2026 [28][60] - The company is closely monitoring geopolitical situations and their potential impacts on operations and costs, maintaining a mature and diversified procurement network [31][59] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [9] - The board proposed a cash dividend distribution plan totaling RMB 5.7 billion in 2026, maintaining a 30% annual cash dividend payout ratio [25] Q&A Session Summary Question: Impact of currency exchange on guidance - Management acknowledged the impact of FX movements but expressed confidence in their execution capabilities and the visibility provided by the CRDMO business model [30] Question: Geopolitical impact on margins - Management noted potential risks to upstream raw material costs but emphasized their operational efficiency and procurement strategies to mitigate impacts [31] Question: Pipeline behind TIDES CapEx budget - Management highlighted the ongoing demand for peptides and the growth potential of oligonucleotides, indicating a focus on multiple modalities [32][33] Question: Client outsourcing strategy changes - Management stated that large pharma's internal manufacturing does not change their commitment to improving capabilities and providing services [35] Question: Current utilization rate of small molecule capacity - Management indicated strong demand and ongoing collaborations with leading companies, enhancing their business in the Biology and Testing sectors [37] Question: Impact of FDA's regulatory changes on drug approvals - Management expressed that any regulatory streamlining would benefit patients and potentially increase demand for drug substances [39] Question: Positioning in oral small molecule GLP-1 CDMO business - Management confirmed strong growth in the small molecule sector, particularly in GLP-1 drugs, and anticipated benefiting from high demand [41][46] Question: Revenue breakdown and geographical mix - Management noted strong growth across all regions, with expectations for continued growth in the U.S., China, and Europe [48][52] Question: Sustainability of TIDES business growth - Management expressed confidence in sustained growth driven by a robust pipeline and ongoing demand for their products [54] Question: Timeline for new facility contributions - Management stated that new facilities in China can become operational in less than 12 months [57] Question: Competitive landscape in siRNA CRO space - Management acknowledged the presence of many players but emphasized their focus on quality, speed, and cost as competitive advantages [62][64] Question: Confidence in new orders and booking assumptions - Management expressed confidence in converting backlog into revenue and maintaining strong execution capabilities [66]

Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6][20] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][21] - The adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [10] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [11] - TIDES revenue nearly doubled, growing 96% year-over-year to RMB 11.37 billion, with a backlog growth of 20.2% [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [7] - Europe and China experienced declines due to fluctuations in project delivery timing [7] Company Strategy and Development Direction - The company remains focused on its integrated CRDMO core business, aiming to enhance global capabilities and operational efficiency [24] - WuXi AppTec plans to maintain a cash dividend distribution plan totaling RMB 5.7 billion in 2026, with a 30% annual cash dividend payout ratio [26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining rapid business growth, expecting total revenue to reach RMB 51.3 billion to RMB 53 billion in 2026, with continuing operations revenue growing 18%-22% year-over-year [24] - The company is closely monitoring geopolitical situations and their potential impact on operations, emphasizing a mature and diversified procurement network [32][60] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [8] - The company completed 741 quality audits and inspections in 2025, maintaining high standards for quality and compliance [9] Q&A Session Summary Question: Impact of currency exchange on guidance - Management acknowledged the impact of FX movements but emphasized strong visibility in their CRDMO business model [30] Question: Geopolitical impact on margins - Management noted that while there are potential risks to raw material costs, they have not seen direct impacts on operations [32] Question: TIDES CapEx and future modalities - Management indicated that while peptide demand remains high, they are also seeing growth in oligonucleotides and complex small molecules [34] Question: Client outsourcing strategy changes - Management stated that large pharma continues to manufacture internally but they remain committed to improving capabilities and providing services [36] Question: Current utilization rate of small molecule capacity - Management highlighted their ability to provide high-quality data, which drives business for their Biology and Testing segments [38] Question: FDA's new trial requirements - Management believes that regulatory streamlining will benefit patients and potentially increase demand for drug substances [40] Question: Positioning in oral small molecule GLP-1 CDMO business - Management confirmed strong growth in the small molecule sector, particularly in GLP-1 drugs [47] Question: Revenue breakdown and geographical mix - Management noted strong growth across all regions, with a focus on customer needs driving geographic revenue growth [49][50] Question: Sustainability of TIDES growth - Management expressed confidence in sustained growth due to a robust pipeline and increasing demand for their products [54] Question: Timeline for new facility contributions - Management stated that new facilities in China can become operational in less than 12 months [57] Question: Impact of Middle East situation on investments - Management reassured that their long-term strategy remains unchanged despite geopolitical tensions [59] Question: Confidence in new orders and revenue guidance - Management expressed confidence in converting backlog into revenue and maintaining growth trajectory [65] Question: WuXi AppTec's position on the 1260H list - Management stated they are confident WuXi AppTec will not be included in the list and will continue to monitor the situation [70]

Financial Data and Key Metrics Changes - The company reported a revenue of RMB 5.9 billion for 2024, reflecting a year-over-year growth of 46.7% [2] - Adjusted net profit margin is projected to be 70%, with a gross profit margin of 22.6% for 2024 [2][6] - The backlog for 2025 is expected to reach USD 1.5 billion, indicating a 50.3% increase compared to 2024 [2] Business Line Data and Key Metrics Changes - The revenue breakdown shows that pre-R&D activities account for 42% of total revenue, with significant contributions from ADC development [2] - The company anticipates strong momentum in ADC development, with a focus on both biotech and pharma sectors [2][3] - The dual-payload ADC format is highlighted as a key innovation area, with expectations for significant market share growth [1][3] Market Data and Key Metrics Changes - The company is targeting a 30% to 35% compound annual growth rate (CAGR) from 2025 to 2030, driven by strong market demand [3][4] - The regional distribution of revenue indicates a strong presence in the US and Europe, collectively contributing to the company's growth strategy [2] Company Strategy and Development Direction - The company is focusing on organic growth and strategic acquisitions to enhance its market position, particularly in the ADC sector [2][3] - There is a strong emphasis on innovation, particularly in payload-linker technology and dual-payload ADC formats, which are expected to drive future revenue [1][3] - The company plans to maintain a robust pipeline with multiple submissions for regulatory approvals anticipated by 2028 [3] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate market volatility and achieve synergy across its operations [4][6] - The outlook for 2025 includes expectations for positive free cash flow and continued investment in CAPEX, projected at RMB 3 billion [2][6] - The management highlighted the importance of maintaining a healthy backlog and ramping up operational capacity to meet future demand [6] Other Important Information - The company is investing heavily in its global footprint, with plans for groundbreaking and commissioning of new GMP sites by 2025 [1][2] - There is a focus on enhancing operational efficiency through AI and technology licensing opportunities [10][11] Q&A Session Summary Question: What is the expected revenue growth for 2025? - The company anticipates a revenue growth of 40% year-over-year for 2025, driven by strong demand in the ADC sector [5] Question: How does the company plan to manage operational capacity? - Management indicated that they are ramping up utilization ratios and maintaining a healthy backlog to ensure operational efficiency [6] Question: What are the key areas of innovation for the company? - The company is focusing on payload-linker technology and dual-payload ADC formats as key areas for innovation and market differentiation [1][3]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was BRL 2.96 billion, a 6% increase quarter-over-quarter, while full-year revenue reached BRL 10.7 billion, growing 46.8% year-over-year [34] - Net Interest Income grew 19% year-over-year to BRL 4.7 billion, with a Net Interest Margin of 12.5% for the year [34] - Net income for Q4 2025 was BRL 215 million, contributing to a full-year net income of BRL 1.05 billion, an increase of 31.8% year-over-year [36] Business Line Data and Key Metrics Changes - Total active customer count increased by 73% in 2025, reaching 6.7 million active clients, with customers averaging over five products each [26] - Total loan balances grew 44% in 2025 to BRL 34.9 billion, with secured loans making up 86% of the portfolio [28] - The market share of payroll credit reached 8.9%, a gain of 250 basis points compared to 2024 [31] Market Data and Key Metrics Changes - The total addressable market for Agibank is estimated at BRL 2.1 trillion, encompassing secure loans from INSS beneficiaries and private/public workers [25] - The Brazilian market for secure loans from INSS beneficiaries is valued at BRL 733 billion, representing approximately 100 million individuals [25] Company Strategy and Development Direction - Agibank's hybrid model combines a fully digital bank with a nationwide retail network of Smart Hubs, targeting underserved segments of the Brazilian population [7][8] - The company plans to invest in technology, particularly AI, to enhance customer experience and operational efficiency [17][109] - Agibank aims to maintain a long-term focus on customer engagement and sustainable growth, prioritizing long-term interests over short-term outcomes [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the normalization of credit origination following temporary suspensions related to INSS agreements, with operations fully resumed [43] - The company anticipates continued market expansion driven by demographic trends, income levels, and educational barriers in Brazil [15][46] - Management believes that competition will not significantly impact their unique positioning in the payroll credit market, as they serve a largely underserved population [44][47] Other Important Information - The coverage ratio for non-performing loans (NPLs) was 189.4% by the end of 2025, indicating strong credit quality [33] - Total deposits increased by 50% from 2024, reaching BRL 37.8 billion, with a balanced funding approach between institutional and retail sources [37] Q&A Session Summary Question: Concerns about INSS relationship and future suspensions - Management reassured that the relationship with INSS is stable, with no expected future suspensions, and operations have normalized [42][43] Question: Competitive environment and interest rates - Management believes their focus on customer experience will mitigate risks from increased competition as interest rates decline [44][45] Question: NPL ratio increase and Net Interest Margin (NIM) decrease - Management explained that the NPL increase was due to a higher share of private payroll credit and temporary origination slowdowns, while NIM was impacted by a mix shift towards secured loans and rising interest rates [62][65] Question: Decline in commissions and fees revenues - Management attributed the decline to the suspension of INSS originations and expects normalization in the future [71] Question: SG&A expenses reduction - Management indicated that the reduction was due to variable costs related to the suspension and a reversal of legal provisions due to AI-driven efficiencies [73][102] Question: Growth outlook for payroll lending - Management expressed confidence in returning to pre-suspension origination levels and sees significant growth potential in both INSS and private payroll lending [87][88]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached BRL 2.96 billion, a 6% increase quarter-over-quarter, while full-year revenue was BRL 10.7 billion, growing 46.8% year-over-year [18] - Net interest income grew 19% year-over-year to BRL 4.7 billion, with a net interest margin of 12.5% for the year [18] - Net income for Q4 2025 was BRL 215 million, contributing to a full-year net income of BRL 1.05 billion, an increase of 31.8% year-over-year [19] Business Line Data and Key Metrics Changes - Total active customers increased by 73% in 2025, reaching 6.7 million, with customers maintaining primary banking relationships averaging over 5 products [14][15] - Total loan balances grew 44% in 2025 to BRL 34.9 billion, with secured loans representing 86% of the total [15] - The private payroll credit portfolio reached BRL 0.9 billion, while unsecured lending expanded 18.3% to BRL 4.8 billion [16] Market Data and Key Metrics Changes - Agibank's market share of payroll credit increased to 8.9%, a gain of 250 basis points compared to 2024 [17] - The total addressable market for Agibank is estimated at BRL 2.1 trillion, encompassing various financial products for approximately 100 million individuals [14] Company Strategy and Development Direction - Agibank's hybrid model combines a digital bank with a nationwide retail network of Smart Hubs, targeting underserved segments of the Brazilian population [6][9] - The company plans to invest heavily in technology, particularly AI, to enhance customer experience and operational efficiency [10][94] - Agibank aims to maintain a long-term focus on customer engagement and sustainable growth, prioritizing long-term interests over short-term outcomes [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the normalization of credit origination following temporary suspensions related to INSS, with expectations for continued growth in the payroll credit segment [40][41] - The company anticipates that demographic trends, education, and income levels in Brazil will support long-term growth opportunities [27][29] - Management highlighted the importance of maintaining a strong relationship with customers and adapting to evolving market conditions [82] Other Important Information - The company maintains a Capital Adequacy Ratio of 15.5% and a Tier 1 capital ratio of 14.2% [21] - Total deposits increased by 50% from 2024, reaching BRL 37.8 billion [20] Q&A Session Summary Question: Concerns about INSS relationship and future suspensions - Management reassured that the relationship with INSS is stable and that operations have fully normalized after recent agreements [25][26] Question: Competitive environment with decreasing interest rates - Management believes that their unique hybrid model positions them well against competition, regardless of interest rate fluctuations [26][27] Question: NPL ratio increase and net interest margin decrease - Management explained that the NPL increase was due to a mix of portfolio changes and temporary production slowdowns, while the NIM decrease was influenced by a shift towards secured lending and market interest rate changes [46][50] Question: Decline in commissions and fees revenues - Management attributed the decline to the suspension of INSS originations and noted that user experience has since normalized [55] Question: SG&A expenses reduction - Management indicated that the reduction was due to variable costs related to the suspension and a reversal of legal provisions due to AI-driven efficiencies [58][62] Question: Growth outlook for payroll lending - Management expressed confidence in returning to pre-suspension origination levels and emphasized sustainable growth strategies for both INSS and private payroll products [70][71]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was BRL 2.96 billion, a 6% increase quarter-over-quarter, while full-year revenue reached BRL 10.7 billion, growing 46.8% year-over-year [19][12] - Net interest income grew 19% year-over-year to BRL 4.7 billion, with a net interest margin of 12.5% for the year [19][20] - Net income for Q4 2025 was BRL 215 million, contributing to a full-year net income of BRL 1.05 billion, an increase of 31.8% year-over-year [20][19] - Total deposits increased by 50% from 2024, reaching BRL 37.8 billion [21] Business Line Data and Key Metrics Changes - Total active customers increased by 73% in 2025, reaching 6.7 million, with customers averaging over 5 products each [15][16] - Total loan balances grew 44% in 2025 to BRL 34.9 billion, with secured loans making up 86% of the portfolio [16][18] - The private payroll credit portfolio reached BRL 0.9 billion, while unsecured lending expanded 18.3% to BRL 4.8 billion [17][18] Market Data and Key Metrics Changes - The addressable market for Agibank is estimated at BRL 2.1 trillion, encompassing secure loans from INSS beneficiaries and other financial products [14] - Agibank's market share of payroll credit reached 8.9%, an increase of 250 basis points compared to 2024 [18] Company Strategy and Development Direction - Agibank's hybrid model combines a digital bank with a nationwide retail network, targeting underserved segments of the Brazilian population [5][6] - The company plans to invest heavily in technology, particularly AI, to enhance customer experience and operational efficiency [10][31] - Agibank aims to maintain a long-term focus on customer engagement and sustainable growth, prioritizing long-term interests over short-term outcomes [11][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the normalization of credit origination following temporary suspensions related to INSS agreements [26][38] - The company anticipates continued growth in the payroll credit market, driven by demographic trends and the need for accessible financial services [28][30] - Management believes that competition will not significantly impact their unique positioning in the market, as they serve a largely underserved population [28][30] Other Important Information - The company maintains a strong capital adequacy ratio of 15.5% and a Tier 1 capital ratio of 14.2% [21] - The coverage ratio for non-performing loans (NPLs) was 189.4% by the end of 2025, indicating strong credit quality [18] Q&A Session Summary Question: Concerns about INSS relationship and future suspensions - Management reassured that the contractual relationship with INSS is stable and that they do not foresee any further suspensions affecting credit origination [26] Question: Competitive environment and interest rates - Management believes their focus on customer experience will mitigate risks from increased competition as interest rates decline [25][28] Question: Impact of INSS payroll lending on results - Management indicated that normalization of credit origination is expected, with a return to pre-suspension levels [38] Question: Dynamics of private payroll lending - Management confirmed a cautious approach to private payroll lending but noted that they are now ready to ramp up production [41][42] Question: NPL ratio increase and net interest margin changes - Management explained that the increase in NPLs was due to a mix effect and temporary production slowdowns, while the net interest margin was impacted by a shift towards secured lending [45][49] Question: Decline in commissions and fees revenues - Management attributed the decline to the slowdown in production and cross-selling during the fourth quarter but expects normalization moving forward [52][53] Question: SG&A expenses reduction - Management clarified that the reduction was due to variable costs related to the suspension and a reversal of legal provisions due to AI-driven efficiencies [55][61]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $8 million, down 3% from $8.2 million in Q4 2024, but at the high end of the pre-announced range of $7.8 million-$8 million [6] - Full year 2025 revenue was $28.5 million, down 7% from $30.8 million in 2024 [7] - Non-GAAP gross margin for Q4 2025 was 43%, up from 42% a year ago; for the full year, it was 47%, up from 35% in 2024, reflecting a 1,200 basis points improvement [8] - Non-GAAP operating expenses for Q4 2025 were $9.7 million, down 9% year-over-year; for the full year, they were $36.6 million, down 47% from $68.9 million in 2024 [9] Business Line Data and Key Metrics Changes - Sold 7,554 nanochannel array flow cells in Q4 2025, down 6% year-over-year; full year flow cells sold were 30,171, down just 0.4% [6][8] - Consumables and software revenue decreased by 1% to $4.8 million in Q4, driven by a 22% decline in software revenue, offsetting 8% growth in consumables [12] - Consumables and software revenue grew for the full year from $19 million to $20.4 million, representing 7% growth [13] Market Data and Key Metrics Changes - The company has narrowed its geographic focus to the United States, Canada, most of Western Europe, and Israel, while maintaining partnerships for support outside these regions [14] - Routine use customers accounted for about 83% of OGM consumables revenue in 2025, with an average revenue per routine use customer of about $89,000 [15][16] Company Strategy and Development Direction - The company shifted its strategy in September 2024 to focus on profitable growth from high volume users and selective customer acquisition [10] - Four strategic pillars were established: support the installed base, increase utilization of optical genome mapping, build support for reimbursement, and improve profitability through lower costs and higher volumes [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong outlook for 2026, initiating revenue guidance of $30 million-$33 million, representing 5%-16% growth over 2025 [25] - A significant catalyst for growth is the increase in the price determination for the hematologic malignancy CPT code, which is expected to accelerate adoption and utilization [32][33] Other Important Information - The company ended 2025 with $29.6 million in cash equivalents and available-for-sale securities, with an expected cash runway extending into 2027 [9] - The establishment of a second Category I CPT code for OGM in constitutional genetic disorders is a key infrastructure development [20] Q&A Session Summary Question: Expectations for new OGM systems installations in 2026 - Management expects installations to be comparable to the previous year but is not providing specific guidance [28] Question: Sales expectations for nanochannel array flow cells in 2026 - Management anticipates that consumables volume will likely track with revenue growth, despite supply constraints affecting sales [29][30] Question: Required sales of nanochannel or new OGM systems to achieve revenue guidance - Management emphasizes focusing on the productivity of routine users and converting potential customers to validated users as key growth drivers [31][32]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $8 million, down 3% from $8.2 million in Q4 2024, but at the high end of the pre-announced range of $7.8 million-$8 million [6] - Full year 2025 revenue was $28.5 million, down 7% from $30.8 million in 2024 [7] - Non-GAAP gross margin for Q4 2025 was 43%, up from 42% a year ago; for the full year, it was 47%, up from 35% in 2024, reflecting a 1,200 basis points improvement [8] - Non-GAAP operating expenses for Q4 2025 were $9.7 million, down 9% year-over-year; for the full year, they were $36.6 million, down 47% from $68.9 million in 2024 [9] - Cash equivalents and available-for-sale securities at year-end were $29.6 million, with expectations for cash runway extending into 2027 [9] Business Line Data and Key Metrics Changes - Sold 7,554 nanochannel array flow cells in Q4 2025, down 6% year-over-year; full year flow cells sold were 30,171, down just 0.4% [6][8] - Consumables and software revenue decreased by 1% to $4.8 million in Q4, driven by a 22% decline in software revenue, offsetting 8% growth in consumables [12] - Consumables and software revenue grew for the full year from $19 million to $20.4 million, representing 7% growth [13] Market Data and Key Metrics Changes - The geographic focus has narrowed to the United States, Canada, most of Western Europe, and Israel, with commercial partners supporting OGM outside these regions [14] - Routine use customers accounted for about 83% of OGM consumables revenue in 2025, with an average revenue per routine use customer of about $89,000 [15] Company Strategy and Development Direction - The company shifted its strategy in September 2024 to focus on profitable growth from high volume users and selective customer acquisition [10] - Four strategic pillars were established: support the installed base, increase utilization of OGM, build support for reimbursement, and improve profitability and scalability [11] - The company aims to increase the number of routine use customers and expand average consumable revenue per routine use site [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong outlook for 2026, initiating revenue guidance of $30 million-$33 million, representing 5%-16% growth over 2025 [25] - A significant catalyst for growth is the increase in the price determination for the hematologic malignancy CPT code, which is expected to accelerate adoption and utilization [32][33] Other Important Information - The company hosted the Bionano Symposium 2026, featuring over 1,250 registrants and discussions on growth opportunities for OGM [22] - The total number of publications related to OGM reached approximately 450 in 2025, reflecting a compound annual growth rate of about 28% since 2020 [19] Q&A Session Summary Question: Expectations for new OGM systems installations in 2026 - Management expects installations to be comparable to the previous year but is not providing specific guidance [28] Question: Sales expectations for nanochannel array flow cells in 2026 - Management anticipates consumables volume to track with revenue growth, despite supply constraints affecting sales [30] Question: Required sales of new OGM systems to achieve revenue guidance - Management emphasizes focusing on productivity of routine users and converting potential customers to validated users as key growth drivers [32]